When we are sleeping, we have the European central bank and their policy decision at 12.30am. Company news Qantas has forecasted a loss at the earnings level of $250 million to $300 million for the first half of financial 2022. The company has been able to accelerate the repair of its balance sheet and expects to finish the first half of financial year 2022 with a materially better net debt position than it had prior to the start of Delta variant lockdowns in June. In the pre open, time of filming, the price is up over 8 per cent. As of yesterday, shares in Qantas (ASX:QAN) closed 0.6 per cent lower at $4.87. Broker moves Citi upgraded CSL (ASX:CSL) to buy from neutral with a price target of $340. CSL is slated to purchase Vifor Pharma at a 65 per cent premium to the company's trading price. Citi estimated that the purchase will be roughly 9 per cent accretive to CSL's net profit after tax prior to amortisation, given CSL's higher trading multiple.